Stock Scorecard

Stock Summary for N/A (ZVRA) - $4.52 as of 4/26/2024 10:02:13 PM EST

Total Score

3 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZVRA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZVRA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZVRA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ZVRA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ZVRA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA 4/28/2024 1:45:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA - Zevra Therapeutics ( NASDAQ:ZVRA ) 4/24/2024 7:40:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA 4/20/2024 4:00:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA - Zevra Therapeutics ( NASDAQ:ZVRA ) 4/16/2024 7:20:00 PM
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting - Zevra Therapeutics ( NASDAQ:ZVRA ) 4/15/2024 9:01:00 PM
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting 4/15/2024 9:01:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA 4/12/2024 1:30:00 PM
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility 4/10/2024 11:30:00 AM
Attention Zevra Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm - Zevra Therapeutics ( NASDAQ:ZVRA ) 4/8/2024 11:04:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA - Zevra Therapeutics ( NASDAQ:ZVRA ) 4/8/2024 7:27:00 PM

Financial Details for ZVRA

Company Overview
Ticker ZVRA
Company Name N/A
Country N/A
Description N/A
Sector Name N/A
Industry Name N/A
Most Recent Quarter N/A
Next Earnings Date N/A

Stock Price History
Last Day Price 4.52
Last Day Price Updated 4/26/2024 10:02:13 PM EST
Last Day Volume 157,431
Average Daily Volume 250,524
52-Week High 0.00
52-Week Low 0.00
Last Price to 52 Week Low 0.00%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE 0.00
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 0.00
Total Cash Per Share 0.00
Book Value Per Share Most Recent Quarter 0.00
Price to Book Ratio 0.00
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A

Share Statistics
Total Shares Outstanding 0
Market Capitalization 0
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 0.00%
Reported EPS 12 Trailing Months 0.00
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.00
Net Income Twelve Trailing Months 0
Net Income Past Year 0
Net Income Prior Year 0
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%

Balance Sheet
Total Cash Most Recent Quarter 0
Total Cash Past Year 0
Total Cash Prior Year 0
Net Cash Position Most Recent Quarter 0
Net Cash Position Past Year 0
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 0
Total Stockholder Equity Prior Year 0
Total Stockholder Equity Most Recent Quarter 0

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.33
MACD Signal -0.34
20-Day Bollinger Lower Band 4.23
20-Day Bollinger Middle Band 5.73
20-Day Bollinger Upper Band 7.23
Beta 0.00
RSI 29.60
50-Day SMA 5.22
200-Day SMA 7.13

System
Modified 3/9/2023 10:48:53 PM EST